Geldanamycin Could Halt Tumors Other Than Breast Cancer
Stopping unwanted blood vessel growth is a key challenge in the battle against cancer, according to Dr Sreenivasan Ponnambalam, reader in human disease biology in the University of Leeds' Faculty of Biological Sciences.
"This is potentially very significant because tumours secrete substances that stimulate blood vessels to develop around them, forming networks that supply nutrients and provide pathways for spread around the body," Dr Ponnambalam said. "This is one of the big problems in cancer: how can we stop the tumour growing and spreading through these blood vessel networks?"
There are already other drugs available that try to stop this growth. One type tries to attack directly the membrane protein VEGFR2, which is essential for new blood vessel growth. However, that approach carries the risk of serious side-effects because proteins in the membrane walls of blood vessels do important work such as controlling blood pressure.
Geldanamycin offers a novel and potentially safer solution because it suppresses the protein indirectly.
The new study, based on experiments with human cells and different animal models, found that geldanamycin indirectly triggered the clearance of the VEGFR2 protein by activating a cellular quality-control system that breaks down many proteins.
That quality-control system already degrades VEGFR2 relatively slowly but the drug accelerates the process, preventing activation of the protein and inappropriate new blood vessel formation.
"With conventional treatments, we have been trying to deal with the situation after the switch has been thrown. What this drug does is destroy the key part of the switch before that switch is thrown," Dr Ponnambalam said.
"Geldanamycin and chemical derivatives have been under intensive study in the laboratory and in clinical trials for the past 20 years. The cost to the NHS or patients could be relatively low compared to the expensive existing anti-cancer drugs, which are still under patent," Dr Ponnambalam added.
The two-year study involved researchers in the University of Leeds and University College London. It was funded by The Wellcome Trust. The paper is published in the journal PLOS ONE.
The full paper: A.F Bruns N. Yuldasheva, A.M. Latham, Caroline Pellet-Many, L. Bao, P. Frankel, S.L. Stephen, G.J. Howell, S.B. Wheatcroft, M.T. Kearney, I.C. Zachary, S. Ponnambalam, "A heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair." PLOS ONE (2012)
University of Leeds
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
University of Leeds. "Geldanamycin Could Halt Tumors Other Than Breast Cancer." Medical News Today. MediLexicon, Intl., 8 Nov. 2012. Web.
25 May. 2017. <http://www.medicalnewstoday.com/releases/252494.php>
University of Leeds. (2012, November 8). "Geldanamycin Could Halt Tumors Other Than Breast Cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.